The Journal of Contemporary Dental Practice

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 23 , ISSUE 2 ( February, 2022 ) > List of Articles

EDITORIAL

Severe Acute Respiratory Syndrome Coronavirus 2 Nosode: A Potential Alternative Vaccine Platform

Kiranam Chatti

Keywords : COVID-19, Nosode, SARS-CoV-2, Variolation

Citation Information : Chatti K. Severe Acute Respiratory Syndrome Coronavirus 2 Nosode: A Potential Alternative Vaccine Platform. J Contemp Dent Pract 2022; 23 (2):133-134.

DOI: 10.5005/jp-journals-10024-3272

License: CC BY-NC 4.0

Published Online: 10-06-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Besides conventional vaccinations, viable alternatives are needed to elicit an immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We propose and highlight the value of a homeopathic approach known as the “nosode” for the prevention of coronavirus disease-2019 (COVID-19). Nosode is an extract prepared from disease-affected tissues which is subsequently processed and administered as an antidote for the same medical condition. This concept might be a crucial therapeutic approach for viral infections since infected tissues contain a wide range of important viral antigens that could induce a functional host response via immunological sensitization. Thereby, nosode preparation produced from SARS-CoV-2-affected tissues may provide protection against COVID-19. “SARS-CoV-2 nosode” warrants more scientific investigation as a viable alternative vaccination platform.


PDF Share
  1. World Health Organization. Weekly epidemiological update on COVID-19. 2022. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—15-march-2022.
  2. Jonas WB. Do homeopathic nosodes protect against infection? An experimental test. Altern Ther Health Med 1999;5(5):36–40. PMID: 10484829.
  3. Shah R. A clinical evaluation of a hepatitis C nosode in the treatment of hepatitis C. J Altern Complement Med 2016;22(3):197–203. DOI: 10.1089/acm.2014.0146.
  4. Bracho G, Varela E, Fernández R, et al. Large-scale application of highly-diluted bacteria for Leptospirosis epidemic control. Homeopathy 2010;99(3):156–166. DOI: 10.1016/j.homp.2010.05.009.
  5. Bagai U, Rajan A, Kaur S. Antimalarial potential of Nosode 30 and 200 against Plasmodium berghei infection in BALB/c mice. J Vector Borne Dis 2012;49(2):72–77. PMID: 22898477.
  6. de Almeida LR, Campos MC, Herrera HM, et al. Effects of homeopathy in mice experimentally infected with Trypanosoma cruzi. Homeopathy 2008;97(2):65–69. DOI: 10.1016/j.homp.2008.02.009.
  7. Gandhi M, Rutherford GW. Facial masking for Covid-19: potential for “variolation” as we await a vaccine. N Engl J Med 2020;383:e101. DOI: 10.1056/NEJMp2026913.
  8. Gandhi M, Beyrer C, Goosby E. Masks do more than protect others during COVID-19: reducing the inoculum of SARS-CoV-2 to protect the wearer. J Gen Intern Med 2020;35(10):3063–3066. DOI: 10.1007/s11606-020-06067-8.
  9. Imai M, Iwatsuki-Horimoto K, Hatta M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A 2020;117:16587–16595. DOI: 10.1073/pnas.2009799117.
  10. https://www.cdc.gov/smallpox/history/history.html.
  11. Rasmussen AL, Escandón K, Popescu SV. Facial masking for Covid-19. N Engl J Med 2020;383(21):2092. DOI: 10.1056/NEJMc2030886.
  12. Brosseau LM, Roy CJ, Osterholm MT. Facial masking for Covid-19. N Engl J Med 2020;383:2092–2093. DOI: 10.1056/NEJMc2030886.
  13. Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203(2):631–637. DOI: 10.1002/path.1570.
  14. Potus F, Mai V, Lebret M, et al. Novel insights on the pulmonary vascular consequences of COVID-19. Am J Physiol Lung Cell Mol Physiol 2020;319:L277–L288. DOI: 10.1152/ajplung.00195.2020.
  15. Watanabe T, Bartrand TA, Weir MH, et al. Development of a doseresponse model for SARS coronavirus. Risk Anal 2010;30(7): 1129–1138. DOI: 10.1111/j.1539-6924.2010.01427.x.
  16. Mukherjee S, Talele G, Chowdhary A, et al. Preparation of Coronavirus nosodes sourced from a clinical sample of SARS-Cov-2 positive patient, inactivated strain, and spike glycoprotein. Int J High Dilution Res 2020;19(4):2–9. DOI: 10.51910/ijhdr.v19i4.1054.
  17. Talele G, Vaidhya S, Chowdhary A, et al. Randomized double-blind, placebo-controlled feasibility study, evaluating the efficacy of homeopathic medicines in the prevention of COVID-19 in a quarantined population. Homeopathy 2022;111(1):49–56. DOI: 10.1055/s-0041-1735235.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.